

Omni Scottsdale Resort & Spa at Montelucia Scottsdale, AZ

		V7 2.17.25 * subject to change
Sunday M	av 4	
6:30 PM	8:00 PM	Welcome Reception - (Hors-d'oeurves, dinner on your own)
Monday M	lay 5	Prove la facada
Day 2 1		Breakfast
		ons in Transfusion Medicine and Cellular Therapeutics: Enhancing ma and Critical Care
derived therap	eutics, cellul critical illnes	rsection of transfusion medicine and regenerative medicine, highlighting advancements in blood- ar therapies, and innovative regenerative products for treating acute and chronic conditions linked ss. Attendees will gain valuable insights into how these innovations can significantly improve
7:30 AM	7:35 AM	Welcome & Introductions
		Shibani Pati MD PhD
		CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF
Session 1	Topics in	n Trauma and Transfusion Medicine
Moderators:		ene" Moore MD FACS, Distinguished Professor of Surgery, Ernest E Moore Shock nter at Denver Health
		well MD, Professor of Surgery, Trauma and Acute Care Surgery, Director, Surgical Critical ship Program, Co-Director, Adult Surgical Intensive Care Unit
7:35 AM	7:55 AM	Injury Mechanisms and Characteristics, Implications for Future Clinical Trial Planning
		Jason Sperry MD MPH FACS Section Chief, Trauma Surgery: Professor of Surgery and Critical Care; Director
	0 45 444	of Acute Care Surgery Fellowship, University of Pittsburgh
7:55 AM	8:15 AM	Cold Stored Platelets for Transfusion in Hemorrhagic Shock and TBI
		Matthew Neal MD FACS
		Watson Chair and Professor of Surgery, Director of Emergency General Surgery, Co-Director, Pittsburgh Trauma and Transfusion Medicine Research Center, Professor of Clinical and Translational Science and Critical Care Medicine, University of Pittsburgh
8:15 AM	8:35 AM	Donor and Recipient Safety and Transfusion Efficacy Research: Past,
		Present and Future
		Michael Busch MD PhD
		Director Emeritus & VP, Vitalant; Professor, Department of Laboratory Medicine, UCSF
8:35 AM	9:00 AM	Avoiding Iatrogenic Resuscitation Injury after Traumatic Brain Injury: Repairing the Blood Brain Barrier John Holcomb MD FACS
		COL, USA (Ret); Professor of Surgery, Department of Surgery, University of Alabama at Birmingham
9:00 AM	9:20 AM	Clinical Trials of Hemorrhage Control Interventions: Why are they so difficult?
		Jan Jansen MD
		Professor, General Surgery Trauma Section, University of Alabama at Birmingham
9:20 AM	9:40 AM	Cell Mediated Fibrinolysis: A Bridge to Organ Regeneration After Ischemia
		Reperfusion Injury
		Hunter Moore MD PhD Surgical Director of Kidney Transplant and Living Donor, AdventHealth
		Transplant Institution at Porter
9:40 AM	9:55 AM	Question & Answer Panel Session 1

10:15 AM	Break & Exhibits
Cellular	Therapies in Acute and Chronic Illness
Clifford Lo	owell MD PhD, Distinguished Professor, Chair of Department of Laboratory Medicine, UCSF
	latthay MD, Professor of Pulmonary Critical Care Medicine; Research Lab Director, Acute and ARDS: Research and Clinical Trials; Critical Care Specialist, UCSF
10:35 AM	Cellular Reprograming in Human Disease Deepak Srivastava MD
	President & Senior Investigator, Gladstone Institutes; Professor, Departments of Pediatrics & Biochemistry & Physics, Gladstone Institute/UCSF
10:55 AM	Repairing the Infarcted Heart Chuck Murry MD PhD
	Chair and Professor, Department of Stem Cell Biology & Regenerative Medicine; Director, Eli and Edyth Broad Center for Regenerative Medicine & Stem Cell Research, Keck School of Medicine of USC
11:15 AM	In Utero Stem cell therapy Spina Bifida, From the Barn to the Bedside Diana L Farmer MD FACS FRCS
	Chair and Distinguished Professor, Department of Surgery, Chief of Pediatric Surgery, Shriner's Hospitals for Children; Founder and Co-director, Center for Surgical Bioengineering, UC Davis
11:35 AM	Lessons Learned from Clinical Trials in Cell Therapy for TBI Charles S Cox Jr MD FACS
	The George and Cynthia Mitchell Distinguished Chair in Neurosciences; Director, Children's Program in Regenerative Medicine; Professor, Department of Pediatric Surgery, UTHealth Houston
11:50 AM	Question & Answer Panel Session 2
12:50 PM	Lunch
Blood D	erived Therapeutics as a Discovery Platform of Novel Regenerative Factors
Haematolog Anirban S	evaert MD PhD FRCP FRCPath, Professor of Transfusion Medicine, Department of gy, University of Cambridge Sen Gupta PhD, Wallace R. Persons Professor of Engineering, Department of Biomedical g, Case Western University
1:10 PM	Blood-based Approaches to Rejuvenate the Aging Brain Saul Villeda PhD
	Associate Professor, Department of Anatomy; Associate Director, Bakar Aging Research Institute, UCSF
1:30 PM	Rescuing Regeneration in Aging Muscle by Manipulating Blood-Borne Factors
	Amy Wagers PhD Chair and Forst Family Professor, Department of Stem Cell and Regenerative Biology; Executive Committee Member, Harvard Stem Cell Institute
1:50 PM	Exercise Plasma to Cure Alzheimer's disease? Ulrik Wisloff PhD
	Professor in Exercise Physiology and Head, CERG and K.G. Jebsen Centre for Exercise in Medicine, Department of Circulation and Medical Imaging; Faculty of Medicine & Health Sciences, NTNU Norway
2:10 PM	Translating Platelet Rich Plasma Research to Clinical Use in Orthopedics
	Anthony Luke MD MPH Professor, Department of Orthopaedic Surgery: Director, Human Performance
2:30 PM	Anthony Luke MD MPH Professor, Department of Orthopaedic Surgery; Director, Human Performance Center, UCSF Freeze-Dried Platelet Derived Hemostatic Agent in Severe Surgical Bleeding: Results of a Pilot Randomized Clinical Trial
2:30 PM	Professor, Department of Orthopaedic Surgery; Director, Human Performance Center, UCSF Freeze-Dried Platelet Derived Hemostatic Agent in Severe Surgical
	Professor, Department of Orthopaedic Surgery; Director, Human Performance Center, UCSF Freeze-Dried Platelet Derived Hemostatic Agent in Severe Surgical Bleeding: Results of a Pilot Randomized Clinical Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen
2:30 PM 2:45 PM	Professor, Department of Orthopaedic Surgery; Director, Human Performance Center, UCSF Freeze-Dried Platelet Derived Hemostatic Agent in Severe Surgical Bleeding: Results of a Pilot Randomized Clinical Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics,
	Cellular Clifford Lo Michael M Lung Injury 10:35 AM 10:55 AM 11:15 AM 11:35 AM 11:35 AM 11:35 AM 11:50 AM 12:50 PM Blood D Cédric Gh Haematolog Anirban S Engineering 1:10 PM 1:30 PM

Session 4	Emergin	g Concepts and Innovative Therapeutics in Critical Care Moderators
Moderators:	Surgery, Co	leal MD FACS, Watson Chair and Professor of Surgery, Director of Emergency General -Director, Pittsburgh Trauma and Transfusion Medicine Research Center, Professor of Translational Science and Critical Care Medicine, University of Pittsburgh
		and MD MPH FACS, Clinical Assistant Professor, Surgery, University of Arizona of Surgery Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery
3:05 PM	3:25 PM	The Immunobiology of ARDS
		Clifford Lowell MD PhD
		Distinguished Professor and Chair of Department of Laboratory Medicine, UCSF
3:25 PM	3:45 PM	Engineering stem cell derived extracellular vesicles and lipid nanoparticles for targeted delivery
		Aijun Wang MD PhD
		Professor and Vice Chair, Departments of Surgery and Biomedical Engineering; Co-director, Center for Surgical Bioengineering, UC Davis
3:45 PM	4:05 PM	MSCs and Bacterial Pneumonia in Mice: Replicating ARDS Phenotypes in Patients
		Michael Matthay MD
		Professor of Pulmonary Critical Care Medicine; Research Lab Director, Acute Lung Injury and ARDS: Research and Clinical Trials; Critical Care Specialist, UCSF
4:05 PM	4:25 PM	Single cell multi-omics reveals outcome based circulating leukocyte cell populations in human trauma
		Timothy R Billiar MD
		Distinguished Professor and Chair, Department of Surgery; Associate Senior Vice Chancellor for Clinical Academics, University of Pittsburgh; Executive Vice President and Chief Scientific Officer, UPMC
4:25 PM	4:45 PM	Early alterations in innate immunity and role in chronic critical illness Joseph Cuschieri MD
		Professor of Surgery and Lab Medicine, Chief of Surgery at Zuckerberg San Francisco General Hospital and Trauma Center; Trauma Medical Director, UCSF
4:45 PM	5:05 PM	Preclinical drug development for ischemic states using large animal models
		Emin Maltepe MD PhD
		Professor, Department of Pediatrics and Neonatology, UCSF
5:05 PM 5:20 PM	5:20 PM 6:00 PM	Question & Answer Session 4
5.20 PM		Poster Session dinator: Elena Nedelcu MD
		Professor Lab Medicine UCSF
6:00 PM	6:45 PM	Reception
6:45 PM	7:05 PM	Keynote What We Do Matters Introduction: Shibani Pati MD PhD
		John Holcomb MD FACS COL USA (Ret), Professor of Surgery, Department of Surgery, University of Alabama at Birmingham
7:05 PM	8:25 PM	Dinner
Tuesday N	4ay 6	
		Breakfast
Day 3 No	ovel Bloc	od Products, Stem Cell Derived Blood, Military Health Session

Talk topics will delve into stem cell-derived blood components and innovative blood products aimed at providing new therapies for trauma and critical care patients. We'll explore recent findings related to plasma-based treatments for conditions such as sepsis, traumatic brain injury, and burns. Additionally, we'll address the regulatory challenges faced in approving these novel products. The day will wrap up with a session on military health, concentrating on optimizing care and identifying gaps in research and the treatment of injured warfighters on the battlefield/pre-Role 2 care. Three main areas of interest will be discussed: 1) management of hemorrhage on the battlefield with novel blood products and therapeutics, 2) management of organ failure on the battlefield, and 3) management of TBI and SCI on the battlefield. A fourth topic on wound management and infection will be covered in a focus group discussion on May 7th.

	Stem Ce	II Derived Blood Components and Novel Blood Products
Moderators:	Jessica Ca	Irdenas PhD, Associate Professor, Department of Surgery, CU Anschutz
	-	blith MD FACS, Associate Professor UCSF Department of Surgery and Lab Medicine, Research ZSFGH
7:30 AM	7:50 AM	Engineered Platelets: Going Beyond Transfusion and Stopping Bleeding
		Cédric Ghevaert MD PhD FRCP FRCPath Professor of Transfusion Medicine, Department of Haematology, University of
7:50 AM	8:10 AM	Cambridge Developing a Whole Blood Substitute - The Inner Workings of the On Demand Blood Program
		Demand Blood Program Vincent B Ho MD MBA
		Chair and Professor, Department of Radiology and Bioengineering, Director, 4D Bio3 Center for Biotechnology, Uniformed Services University of the Health Sciences
8:10 AM	8:30 AM	Platelet-inspired Synthetic Nanomedicine for Targeted Hemostatic Applications
		Anirban Sen Gupta PhD
		Wallace R. Persons Professor of Engineering, Department of Biomedical Engineering, Case Western University
8:30 AM	8:50 AM	The Hidden Components: Extracellular Vesicles and Mitochondrial DNA in Blood Products Philip Norris MD
		Director of Laboratory Science and VP of Research and Scientific Programs, Vitalant; Professor, Department of Laboratory Medicine, UCSF
8:50 AM	9:10 AM	Translational Applications of Platelet Lysates and Extracellular Vesicles:
		Why, What, and How Thierry Burnouf PhD
		Distinguished Professor and Vice Dean, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University
9:10 AM	9:30 AM	Gene-edited iPSC Derived RBCs for Large Scale Production Kyle Cromer PhD Assistant Professor, UCSF Department of Surgery
9:30 AM	9:45 AM	Question & Answer Session 5
9:45 AM	10:05 AM	Break & Exhibits
		Therapeutics in Trauma, Burns, Sepsis
		A A A A A A A A A A A A A A A A A A A
	Martin A S	chreiber MD FACS FCCM, COL, MC, USAR, Adjunct Professor of Surgery, USUHS
		ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc
		ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD
Moderators:	Joseph Ra	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation
Moderators:	Joseph Ra 10:25 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the
Moderators:	Joseph Ra 10:25 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular
Moderators: 10:05 AM 10:25 AM 10:45 AM	Joseph Ra 10:25 AM 10:45 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University Plasma in Septic Shock; Results of a Randomized Clinical Pilot Trial
Moderators: 10:05 AM 10:25 AM 10:45 AM	Joseph Ra 10:25 AM 10:45 AM 11:05 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University
Moderators: 10:05 AM 10:25 AM 10:45 AM 11:05 AM	Joseph Ra 10:25 AM 10:45 AM 11:05 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University Plasma in Septic Shock; Results of a Randomized Clinical Pilot Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics,
Moderators: 10:05 AM 10:25 AM	Joseph Ra 10:25 AM 10:45 AM 11:05 AM 11:25 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University Plasma in Septic Shock; Results of a Randomized Clinical Pilot Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6 Special Lecture Acellular Tissue Engineered Vessels: Civilian and Military Experience
Moderators: 10:05 AM 10:25 AM 10:45 AM 11:05 AM 11:25 AM	Joseph Ra 10:25 AM 10:45 AM 11:05 AM 11:25 AM 11:40 AM	ppold MD, CAPT (Ret) US Navy, Medical Director, Cellphire, Inc Mitigating the Coagulopathy in Trauma with Anti-Thrombin III Jessica Cardenas PhD Associate Professor, Department of Surgery, CU Anschutz Defining the Endotheliopathy and Epitheliopathy of Trauma and the Impact of Blood Product Resuscitation Shibani Pati MD PhD CTTACC Conference Chair; Director Center for Research in Transfusion Med and Cell Therapies; Vice Chair and Professor, UCSF Endotheliopathy, Fibrinolysis, and Plasma Resuscitation in Burn Shock Jeff Shupp MD Professor of Surgery, Plastic Surgery, Biochemistry, Cellular & Molecular Biology, Georgetown University Plasma in Septic Shock; Results of a Randomized Clinical Pilot Trial Jakob Stensballe MD PhD Board Member, The Medical Society of Copenhagen (DMSK); Senior Consultant, Department of Anesthesiology and Centre for Head & Orthopedics, Rigshospitalet, Copenhagen Question & Answer Session 6

12:00 PM	1:00 PM	Lunch
1:00 PM	1:20 PM	Special Lecture (Tentative)
		Introduction: Mary Homer PhD
		Peter Marks MD PhD
Sector 7	Militer	Director, Center for Biologics Evaluation and Research (CBER) FDA
		Health Session Focused on Battlefield Strategies for Care
Moderators:	of Alabama	omb MD FACS, COL USA (Ret); Professor of Surgery, Department of Surgery, University at Birmingham
	Surgical Res	Gurney MD FACS, Chief, Joint Trauma System, COL MC USA; US Army Institute of search, Fort Sam Houston
1:20 PM	1:35 PM	Distinguished Presentation
		Stephen Ferrara MD CAPT USN (Ret), Acting Assistant Secretary of Defense for Health Affairs
1:35 PM	1:55 PM	Preparations for Large Scale Combat Operations: Joint Trauma System
		Standpoint Jennifer Gurney MD FACS
		Chief, Joint Trauma System, COL MC USA; US Army Institute of Surgical Research, Fort Sam Houston
1:55 PM	2:15 PM	The Combat Casualty Care Peacetime Effect at a Cross Roads: Are we
		Preparing to Fail or Win? (Civilian Perspective)
		Jeremy Cannon MD FACS
		Col USAF (Ret), Professor of Surgery, University of Pennsylvania
2:15 PM	2:35 PM	Blood Replacement Strategies in Future Large-Scale Operations Novel Blood Products
		Martin A Schreiber MD FACS FCCM
		COL, MC, USAR, Adjunct Professor of Surgery, USUHS
Topic 1 M	lanageme	ent of Hemostasis and Hemorrhagic Shock on the Battlefield/pre-Role 2
Moderators:	Andre Cap	MD PhD, Travis M Polk MD FACS
2:35 PM	2:50 PM	The Future of Battlefield Hemmorhage Control
		Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC),
		Defense Health Agency
2:50 PM	3:05 PM	Blood on the Battlefield; When will we Finally get back to WWII Capabilities
		Andre Cap MD PhD COL USA (Ret); Board Director and Chief Scientific Officer, Velico
3:05 PM	3:35 PM	Panel Discussion
3.03 FM	2.22	 Novel/alternate blood products regulatory approval (dried plasma, dried platelets, dried cryo, blood derived products, whole blood, oxygen carriers, blood substitutes) 2). Logistics and Transport of product/patient (containers) 3). Battlefield Regulatory approval Laura Ruse Brosch RN PhD, Andre Cap MD PhD, Jeremy Cannon MD FACS,
		Mike Fitzpatrick PhD, Toby Silverman MD MPH, Ralph R. Vassallo, MD, FACP, Pampee Young MD PhD - To Be Finalized
3:35 PM	3:50 PM	Break
		ent of Traumatic Brain Injury and Spinal Cord Injury on the Battlefield/pre-
Moderator:	Geoffrev Lii	ng MD PhD
3:50 PM	4:05 PM	Title of Talk TBA
		Geoffrey Ling MD PhD
		COL USA (Ret) Professor of Neurolgy USUHS, Professor of Neurology, Johns Hopk
4:05 PM	4:20 PM	TBI Care in Prehospital, Combat and Austere Environments: New Brain Trauma Foundation Guidelines
		GJ Hawryluk MD
		Neurosurgeon, Cleveland Clinic; Adjunct Associate Professor of Neurosurgery, Uniformed Services University; Medical Director and Scientific Advisory Board Chair, Uniformed Services University
4:20 PM	4:50 PM	Panel Discussion
		1). Novel blood products and resuscitation (plasma for TBI, dried platelets) 2). Point of Care Devices- Biomarkers for TBI and SCI evaluation, ICP monitoring, MOBI? 3). Cell Therapies/Regenerative interventions 4). Logistics and Transport for TBI and SCI
		Charles S Cox Jr MD FACS, James Guest MD PhD, GJ Hawryluk MD, Jan Jansen MD, Susan Rowell MD, Jason Sperry MD, Christopher Barrett MD- To Be Finalized

Topic 3 | Management of Organ Failure and Sepsis

Moderator:	Kevin Chur	ng MD
4:50 PM	5:05 PM	Long term organ support in a wartime setting Kevin Chung MD COL USA (Ret), CEO Seastar Medical
5:05 PM	5:20 PM	Renal Replacement Therapy in Large Scale Combat Operations Ian Stewart MD
		Col, USAF, MC, Vice chair for Clinical Research, Professor of Medicine, Uniformed Services University
5:20 PM	5:35 PM	Autologous vs Allogeneic Mesenchymal Stromal Cells for ARDS and Multiorgan Failure Managment: Present and Future Applications Andriy Batchinsky MD
		Professor of Surgery & Medicine, USU, Geneva Foundation, AREVA
5:35 PM	6:05 PM	Panel Discussion1). Novel blood products and resuscitation- dried plasma/ platelets. 2). Cellular Therapies 3).Devices for organ failure support: mobile dialysis, ECMO. 4). Logistics Transport
		Andriy Batchinsky MD, Ernest "Gene" Moore MD FACS, Jakob Stenseballe MD PhD- To Be Finalized
6:05 PM	6:15 PM	Summary of Thoughts and Military Health Session- Future Research Directions of DOD Lester Martinez-Lopez MD MG USA (Ret)
		Former Assistant Secretary of Defense for Health Affairs (ASDHA)
		Jennifer Gurney MD FACS
		Chief, Joint Trauma System, COL MC USA; US Army Institute of Surgical Research, Fort Sam Houston
		John Holcomb MD FACS
		COL USA (Ret); Professor of Surgery, Department of Surgery, University of Alabama at Birmingham
6:15 PM	7:00 PM	Reception
7:00 PM	7:20 PM	2025 Keynote Transforming Battlefield Trauma Care
		Introduction: John Holcomb MD FACS
		Frank Butler MD FAAO FUHM
		CAPT Medical Corps USN (Ret) Consultant in Tactical Combat Casualty Care Joint Trauma System, Adjunct Professor of Military and Emergency Medicine Uniformed Services University, Presidential Citizens Medal Recipient 2024
7:20 PM	9:50 PM	Dinner/CTTACC Awards Presentation
Wednesd	lay May 7	7
7:00 AM	8:00 AM	Exhibitor Takedown

Breakfast

Day 4 | Cell and Gene Editing of Stem Cell and Blood Products, Funding Panel and Round Table Discussions

Talks will focus on exciting advancements in cell and gene editing, as well as the potential for scaling up the production of enhanced, personalized blood and cell therapies for trauma and critical care patients, outside of onocological applications. We'll also tackle the regulatory challenges involved in getting these innovative products approved. The day will conclude with a stakeholder session by major funders of research in this field. After lunch, we'll host focus group discussions centered on the development of dried blood products and wound and tissue healing.

Session 8 | Advancing the field of Cell and Gene Editing

Moderators:	Fabio Triolo, DdR, MPhil, PhD, The Clare A. Glassell Distinguished Chair, Director, Cellular Therapy Core, Professor, Program in Regenerative Medicine		
	David Str	oncek MD, Director, Center for Cellular Engineering, National Institutes of Health	
7:30 AM	7:50 AM	Manufacturing Cell and Gene Therapies in the Academic Setting	
		Brian Shy MD PhD	
		Assistant Professor, Department of Laboratory Medicine,Director, Human Islet and Cellular Transplantation GMP Facility, UCSF	
7:50 AM	8:10 AM	Improving on Nature: Interface Re-engineering of Ligand-based CAR T Cells for Enhanced Efficacy	
		Arun Wiita MD PhD	
		Professor, Department of Laboratory Medicine; Assistant Director, Clinical Cytogenics Laboratory, UCSF	
8:10 AM	8:30 AM	CAR T-Cell Manufacturing Challenges	
		David Stroncek MD	
		Director, Center for Cellular Engineering, National Institutes of Health	
8:30 AM	8:50 AM	High-Throughput Cell Modification	

		Brett Janis PhD
8:50 AM	9:10 AM	CEO/CSO, Treasurer and Co-founder, DesiCorp Inc.
0.30 AM	9.10 AM	Leveraging the Platelet Transcriptome to Decipher Platelet Function and Dysfunction: In Circulation and In Storage
		Lucy Kornblith MD FACS
		Associate Professor UCSF Department of Surgery and Lab Medicine, Director of Research ZSFGH
-	•	erapeutics Insights into Potency and Informative Assays
9:10 AM	9:30 AM	Defining Oxygen Transport Potency for RBCs and Bio-synthetic Alternatives Allan Doctor MD
		Professor University of Maryland Department of Pediatrics
9:30 AM	9:50 AM	Informative Assays to Guide Clinical Development of Novel Blood Products
		Larry Corash MD
		Senior Vice President and Chief Scientific Officer, Cerus Corporation
9:50 AM	10:10 AM	Title of Talk TBA
10:10 AM	10:25 AM	Question & Answer Panel Session 9
10:25 AM	10:40 AM	
10:40 AM	11:00 AM	Special Lecture Integrative Approaches to Managing Chronic Critical Illness – Is it Ready for Prime Time? Sangeeta Pati MD FACOG ABOIM
		Director Sajune Institute for Regenerative Medicine and Founder of Take My Power Back Initiative
Session 9	Regulate	ory Guidance for Trials and Novel Products
Moderators:	Bethany L American R	- Brown, PhD, MSCS , Senior Director, Transfusion Innovation and Product Development, ed Cross
	Beth Shaz University	MD MBA, Professor and Deputy Director of Marcus Center for Cellular Cures, Duke
11:00 AM	11:30 AM	Panel Discussion
		Laura Ruse Brosch RN PhD
		COL ANC USA (Ret); Assistant Vice President for Research Initiatives and Compliance, Uniformed Services University of the Health Sciences
		Bethany L Brown, PhD, MSCS
		Senior Director, Transfusion Innovation and Product Development, American Red Cross
		Andre Cap MD PhD
		-
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA)
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC),
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC),
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency Beth Shaz MD MBA Professor and Deputy Director of Marcus Center for Cellular Cures, Duke
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency Beth Shaz MD MBA Professor and Deputy Director of Marcus Center for Cellular Cures, Duke University
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency Beth Shaz MD MBA Professor and Deputy Director of Marcus Center for Cellular Cures, Duke University Toby Silverman MD MPH Subject Matter Expert, Tunnell Government Services, contractor to BARDA (Former Deputy Associate Director for Medical Affairs, FDA Office of Blood Research and Review) Ralph R. Vassallo, MD, FACP
		COL USA (Ret); Board Director and Chief Scientific Officer, Velico Adam Gerber MD PhD Scientific and Medical Director, Critical Care, Octapharma USA Mary Homer PhD Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) Jenifer Ojeda PhD Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP) Travis M Polk MD FACS CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency Beth Shaz MD MBA Professor and Deputy Director of Marcus Center for Cellular Cures, Duke University Toby Silverman MD MPH Subject Matter Expert, Tunnell Government Services, contractor to BARDA (Former Deputy Associate Director for Medical Affairs, FDA Office of Blood Research and Review)

Session 10 | Stakeholders Panel

This session is focused on discussions concerning the scope for funding in the future for pre-clinical and clinical studies in trauma and critical care, regenerative medicine, cellular therapies and novel blood or blood derived products.

11:30 AM 12:25 PM

1

1

1

DOD

Panel Discussion

Travis M Polk MD FACS

CAPT USN; Director, DoD Combat Casualty Care Research Program; Chair, Joint Program Committee-6; Director, Combat Casualty Care Research Program (CCCRP); US Army Medical Research and Development Command (USAMRDC), Defense Health Agency

Jenifer Ojeda PhD

Program Manager, Regenerative Medicine and Wound Management Combat Casualty Care Research Program (CCCRP)

Therese West PhD

Civilian Deputy Director, US Army Combat Casualty Care Research Program

ARPA-H

Amy Jenkins PhD

Director of Health Science Futures, Program Manager Biotechnologies Office

BARDA

Mary Homer PhD

Chief, United States Radiological and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA)

DARPA

Peter Attilio PhD CRNA

COL USA, Defense Advanced Research Projects Agency (DARPA)

MTEC Shawn Green PhD

President, Medical Technology Enterprise Consortium (MTEC)

DHA/USSAMDA

Kendra L Lawrence PhD BCE PMP

Project Manager, WPAC PMO

12:25 PM	1:25 PM	Lunch
Session	11 Focus (Groups
1:25 PM	3:25 PM	Focus Group 1 From Battlefield to Bedside: Overcoming Challenges in Developing a Dried Plasma Product for Military and Civilian Use
	Moderators:	Anthony Pusateri PhD Chief Scientist, Leidos and Naval Medical Research Unit
		Isabel Lauren Jackson PhD Founding Principal, True North BioPharma, LLC
		Discussion Points Barriers to dried plasma implementation 2). Supply by Blood Centers and Donors 3). Regulatory Outlook 4). Data and research needed 5). Experience and lessons learned for clinical development and FDA approval 6). Opportunities for distribution through pharmacy or blood banks Challenges posed by development of products such as whole blood 8). Emergency use authorizations for civilians 9). Potential in hospital utilization of dried plasma
1:25 PM	3:25 PM	Focus Group 2 Next-Generation Solutions for Wound Healing and Tissue Regeneration
	Moderators:	Geoffrey Gurtner MD FACS Chair Department of Surgery; Professor Surgery; Professor Biomedical Engineering, University of Arizona College of Medicine

Shawn Green PhD

President, Medical Technology Enterprise Consortium (MTEC)